Kurs & Likviditet
|Industri||Läkemedel & Handel|
|2021-07-23||Extra Bolagsstämma 2021|
|2021-04-29||Ordinarie utdelning DANCAN 0.00 DKK|
COPENHAGEN, Denmark, 7 May 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma") hereby on behalf of Tetra Bio-Pharma Inc. ("Tetra"), announce the start of the REBORN1© clinical trial. This trial is designed to evaluate the effect of the company's inhaled proprietary drug formulation, QIXLEEF™, against immediate release oral morphine sulfate on onset of pain relief in people living with cancer. QIXLEEF™ is a botanical drug product with a "fixed ratio" of THC and CBD and is inhaled through a Class 2 medical device vaporizer.
- First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment
- QIXLEEF™ has the potential to transform the pain market
Dr. Guy Chamberland, CEO and CRO of Tetra commented, "Today we recognize an important milestone in advancing the clinical development of this new potential therapeutic for people living with cancer pain. Cancer pain is usually managed with a strong opioid. We believe QIXLEEF™, if proven to be safe and effective, would provide patients with cancer pain a safer treatment option with potentially greater benefits than the current standard of care. QIXLEEF™ may in fact transform the pain market, an area that has been stagnant for many years. Tetra has spent years studying the inhalation of cannabinoids from both synthetic and botanical sources. This research has shown that our investigational new drug, when used with a proprietary medical device, can deliver to patients a reproducible and consistent profile of cannabinoids. The graph below demonstrates the consistency of the inhaled delivery of THC and CBD. We confirm that QIXLEEF™ has arrived in the United States and the trial activities are set to begin."
REBORN1© is being conducted in the United States in collaboration with the Hassman Research Institute, a clinical research organization, who will enroll twenty adults living with breakthrough cancer pain (BTcP) and currently taking stable opioid treatment for breakthrough pain. This innovative Phase 2 pilot, proof-of-concept open-label crossover comparison study will assess whether inhaled QIXLEEF™ will control BTcP faster than immediate-release morphine sulfate tablets.
About Breakthrough Cancer Pain
Cancer causes pain in up to 70% of the patients it affects, with over 33% of those patients describing pain as distressing or even intolerable. People with cancer pain may experience persistent background pain (more that 12 hours per day) and episodic acute pains (breakthrough pain) with an overall reduction in their health-related quality of life (Zeppetella and Davies 2013).
BTcP is defined as "a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger (incident pain), despite relatively stable and adequately controlled background pain" (Davies et al. 2009). Our goal is to decrease and manage this pain and improve the overall quality of life for people with cancer pain.
About the Hassman Research Institute
The Hassman Research Institute (HRI) is a leading clinical research organization that conducts studies in a wide variety of therapeutic areas. HRI's highly trained and experienced staff, including four board certified clinical investigators, is dedicated to maintaining the highest standard of quality results in the trials they conduct.
For more information visit: www.hritrials.com
About Tetra Bio-Pharma
Tetra Bio-Pharma(TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About DanCann Pharma A/S
DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.
DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen. For more information, visit: www.dancann.com
For further information, please contact:
Jeppe Krog Rasmussen, CEO